Nureca Limited FY26 Results and Expansion Plans

Consolidated Revenue: ₹146.96 crore (FY26)
Standalone Revenue: ₹147.21 crore (FY26)

Reader Takeaway: Strong topline growth and significant capex signal expansion, but watch Q4 standalone loss and CFO transition.

What just happened

Nureca Limited announced its financial results for the year ended March 2026. Consolidated revenue grew by approximately 34% to ₹146.96 crore from ₹109.66 crore in the previous year. Standalone revenue also increased by about 28% to ₹147.21 crore from ₹114.64 crore.

The company's board approved an incremental capital expenditure (capex) of up to ₹100 crore. This investment will be used for plant and machinery to manufacture medical devices, healthcare consumables, and hygiene products at their existing land in Derabassi, Punjab. Additional land may also be acquired for future expansion.

Why this matters

The substantial revenue growth indicates increasing market demand for Nureca's products. The ₹100 crore capex signals a strong intent to scale up domestic manufacturing capabilities, potentially improving margins and reducing import dependence in the long run. This expansion is focused on the home healthcare and wellness segments.

The backstory

In the previous fiscal year (FY25), Nureca reported a standalone loss of ₹0.67 crore, but has now moved to a standalone profit of ₹0.30 crore in FY26. Consolidated profit also saw a significant jump from ₹0.85 crore in FY25 to ₹2.08 crore in FY26.

What changes now

Nureca will be significantly increasing its manufacturing capacity for medical devices and consumables. This expansion is expected to drive future revenue streams and market share. The company is also undergoing a transition in its chief financial officer role, with Chander Kant appointed as the new CFO.

Risks to watch

While annual results show growth, a standalone loss was reported for the quarter ended March 31, 2026. This suggests potential quarterly volatility in operations. The successful integration of the new CFO and the execution of the ₹100 crore capex plan will be crucial.

Peer comparison

(No peer comparison data available in the filing.)

Context metrics (time-bound)

• Consolidated Revenue FY26: ₹146.96 crore (vs. ₹109.66 crore FY25)
• Standalone Revenue FY26: ₹147.21 crore (vs. ₹114.64 crore FY25)
• Consolidated PAT FY26: ₹2.08 crore (vs. ₹0.85 crore FY25)
• Standalone PAT FY26: ₹0.30 crore (vs. ₹(0.67) crore FY25)
• Approved Capex: ₹100 crore

What to track next

Investors will be watching the progress of the new manufacturing facility's setup and its impact on production and profitability. Monitoring the financial performance under the new CFO and the company's ability to sustain revenue growth will be key.